Kowa Company Limited

Takeshi Doi

Masahiro Tamura

Yoshinori Kyotani

Toshiaki Oda

Yukiyoshi Yamazaki

Masahiro Nishikawa

Tatsuhiko Kodama

Shunji Takemura

Masao Ohkuchi

Hiroyuki Ishiwata

Masanori Ashikawa

Takahiro Kitamura

Toshiharu Morimoto

Tatsuaki Nishiyama

Hajime Yamada

Akio Iwasaki

Shigeru Kimura

Junya Tagashira

Yushi Saino

Gen Watanabe

Syunji Takemura

Akiyasu Koketsu

Satoshi Goda

Masaki Yamabi

Tetsuya Ishikawa

Seiichi Sato

Manabu Shibasaki

Yoshiharu Miyake

Yuichiro Tabunoki

Takatoshi Ozawa

Ryota Shigemi

Tatsuhiko Kodoma

Akiyasu Kouketsu

Disclosed is a compound which has a low molecular weight and has an activity of enhancing the production of EPO and/or an activity of enhancing the production of hemoglobin. Specifically disclosed is and EPO production enhancer and/or a hemoglobin production enhancer comprising a 1-acyl-4-(substituted oxy, substituted amino, or substituted thio)-1,2,3,4-tetrahydroquinoline derivative, more specifically a tetrahydroquinoline compound represented by general formula (1) [wherein R, R, R, Rand Rindependently represent a hydrogen atom, a Calkyl group, or the like; R, R, R, R, R, Rand Rindependently represent a hydrogen atom, a halogen atom, a Calkyl group, or the like; A represents N&#x2014;R, a sulfur atom, or an oxygen atom; Rrepresents a hydrogen atom, a Calkyl group, or the like; B represents a Caryl group, or a 5- to 10-membered heterocyclic group; and n represents an integer of 0 or 1], a salt of the tetrahydroquinoline compound, or a solvate of the tetrahydroquinoline compound or the salt.

Prophylactic and/or therapeutic agent for anemia comprising tetrahydroquinoline compound as active ingredient

Disclosed is a compound which has a low molecular weight and has an activity of enhancing the production of EPO and/or an activity of enhancing the production of hemoglobin. Specifically disclosed is and EPO production enhancer and/or a hemoglobin production enhancer comprising a 1-acyl-4-(substituted oxy, substituted amino, or substituted thio)-1,2,3,4-tetrahydroquinoline derivative, more specifically a tetrahydroquinoline compound represented by general formula (1) [wherein R, R, R, Rand R' independently represent a hydrogen atom, a Calkyl group, or the like; R, R, R, R, R, Rand Rindependently represent a hydrogen atom, a halogen atom, a Calkyl group, or the like; A represents N&#x2014;R, a sulfur atom, or an oxygen atom; Rrepresents a hydrogen atom, a Calkyl group, or the like; B represents a Caryl group, or a 5- to 10-membered heterocyclic group; and n represents an integer of 0 or 1], a salt of the tetrahydroquinoline compound, or a solvate of the tetrahydroquinoline compound or the salt.

The present invention provides a low molecular weight compound having EPO production-promoting action and/or hemoglobin production-promoting action. The present invention relates to a fused piperidine compound represented by the following general formula (1): (wherein, ring A represents a Caryl group or 5- to 10-membered heterocyclic group, X represents N&#x2014;R, a sulfur atom or an oxygen atom, R, R, R, Rand Rindependently represent a hydrogen atom, Calkyl group or Ccycloalkyl group, and R, Rand Rindependently represent a hydrogen atom or halogen atom), or a salt thereof, or a solvate thereof.

Fused piperidine compound and pharmaceutical containing same

To provide a novel JAK3 inhibitor that is useful as a preventive and/or therapeutic agent for rejection and graft versus host disease (GvHD) in organ transplantation, rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, Sj&#xf6;gren syndrome, Behcet's disease, type I diabetes mellitus, autoimmune thyroiditis, idiopathic thrombocytopenic purpura, ulcerative colitis, Crohn's disease, asthma, allergic rhinitis, atopic dermatitis, contact dermatitis, urticaria, eczema, psoriasis, allergic conjunctivitis, uveitis, cancer, leukemia and the like. The pyridine-3-carboxyamide derivative represented by the general formula (1): or its salt or a solvate thereof.

Pyridine-3-carboxyamide derivative

A cyclic diamine compound of formula (1): wherein Rand Rare individually a hydrogen atom or a methoxy group, provided Ris a methoxy group when Ris a hydrogen atom, or a hydrogen atom when Ris a methoxy group; A is an oxygen atom, a sulfur atom, CH&#x2550;CH, CH&#x2550;N or NR, in which Ris a hydrogen atom, or a lower alkyl, hydroxy lower alkyl, lower alkoxy lower alkyl, aryl or aryl lower alkyl group; B is a nitrogen atom, CH or CR, in which Ris a hydrogen atom, or a lower alkyl, hydroxy lower alkyl, lower alkoxy lower alkyl, aryl or aryl lower alkyl group; m is 1 or 2; and n is a number of 1 to 5,an acid-addition salt thereof, or a hydrate thereof. The compound has inhibitory effects on cell adhesion and is useful for treatment of allergy, asthma, rheumatism, arteriosclerosis, and inflammation.

Cyclic diamine compound with condensed-ring groups

A cyclic amine compound represented by the following general formula (1):wherein, These compounds have inhibitory effects on both cell adhesion and cell infiltration and are useful as anti-asthmatic agents, anti-allergic agents, anti-rheumatic agents, anti-arteriosclerotic agents, anti-inflammatory agents, anti-Sjogren's syndrome agents or the like.

Cyclic amine compounds and pharmaceutical composition containing the same

Unsymmetrical cyclic diamine compound

Cyclic diamine compound with 6-membered ring groups

Cyclic diamine compound with 5-membered ring groups

Piperazine derivative

Thrombin-binding substances capable of promoting anti-thrombin III activity and inhibiting platelet aggregation, and by themselves possessing anti-thrombin activity are disclosed. The thrombin-binding substances are useful as an effective component of anticoagulant agents, and can be produced inexpensively on a large scale.

DNA encoding a human thrombomodulin having a modified glycosaminoglycan

Growing community of inventors

Higashimurayama, Japan

Takeshi Doi